Efficacy and Safety of Fibroblast Growth Factor 21 Analogues for Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis
Annals of Nutrition and Metabolism · 2024
DOI: 10.1159/000541583 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Nutrition and Metabolism, 2024. Verfasst von Fabiana Dolovitsch de Oliveira und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil, fabiana.oliveira@ufcspa.edu.br. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Introduction
Fibroblast growth factor 21 (FGF21) analogues may benefit patients with metabolic dysfunction-associated steatohepatitis (MASH). We aimed to compare the efficacy and safety of FGF21 analogues versus placebo for treating patients with MASH in randomized controlled trials (RCTs).
Methods
We searched PubMed, Embase, and the Cochrane Library. Primary outcomes were fibrosis improvement ≥1 stage without worsening of MASH and MASH resolution without worsening of fibrosis. Secondary outcomes were relative reduction ≥30% of the hepatic fat fraction (HFF) measured by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) and adverse events (AEs).
Results
We included 7 RCTs (886 patients). FGF21 analogues had a higher probability of fibrosis improvement ≥1 stage without worsening of MASH (RR: 1.54; 95% CI: 1.07, 2.22), MASH resolution without worsening of fibrosis (RR: 3.31; 95% CI: 1.80, 6.06), and reduction ≥30% in the HFF by MRI-PDFF (RR: 3.03; 95% CI: 2.12, 4.33) than placebo, without significant difference in the risk of AEs. Subgroup analyses by the stage of fibrosis showed that FGF21 analogues improved fibrosis only among patients with fibrosis stages F1–F3.
Conclusion
FGF21 analogues appear to be an effective and safe treatment option for patients with MASH, although the impact on fibrosis improvement may be limited to non-cirrhotic patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil, fabiana.oliveira@ufcspa.edu.br.
- Department of Medicine, Universidad de Buenos Aires, Buenos Aires, Argentina.
- Department of Medicine, Pontifícia Universidade Católica de Campinas, Campinas, Brazil.
- Department of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
- Department of Internal Medicine, Feevale University, Novo Hamburgo, Brazil.
Zitieren
APA
Dolovitsch de Oliveira, F., Khalil, S. M., Sato, E. D. B. S., de Souza, M. H. G., & Meine, G. C. (2024). Efficacy and Safety of Fibroblast Growth Factor 21 Analogues for Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis. Annals of Nutrition and Metabolism. https://doi.org/10.1159/000541583
Vancouver
Dolovitsch de Oliveira F, Khalil SM, Sato EDBS, de Souza MHG, Meine GC. Efficacy and Safety of Fibroblast Growth Factor 21 Analogues for Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis. Annals of Nutrition and Metabolism. 2024. doi:10.1159/000541583
BibTeX
@article{DolovitschdeOliveira2024,
author = {Dolovitsch de Oliveira, Fabiana and Khalil, Samira Mohamad and Sato, Emmily Daiane Buarque de Santana and de Souza, Matheus Henrique Gonçalves and Meine, Gilmara Coelho},
title = {Efficacy and Safety of Fibroblast Growth Factor 21 Analogues for Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis},
journal = {Annals of Nutrition and Metabolism},
year = {2024},
doi = {10.1159/000541583}
}
EUVIMED